{"name":"VM Oncology, LLC","slug":"vm-oncology-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQY20xUElOVjYxMjRlMDFqQkktODRIMWtFU0g3VUIxQWk0ei1wOHlKdnhVWXJKWDRNaS1sSUduVnI3R0N2TkV1WE1ORmtMbEtUelZITWg4X0c5RkRyVHpZWmxkSTFWc29QajV2VHppU1NncHhYLTdWWGJ0eUVkby1MYm82bVllUG1uVlVSakFSazRmQVJjaklDeUJKMA?oc=5","date":"2026-03-24","type":"trial","source":"openPR.com","summary":"Mesothelioma Clinical Trial Pipeline Appears Robust With 45+ - openPR.com","headline":"Mesothelioma Clinical Trial Pipeline Appears Robust With 45+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxOQnVMZjBIMnRadVZZWkJTZGdNU3E0YkV6blU4ZTZwbEVuV09udVJvZDEzTFRmcjhjb1NhRDctNktxUHA1SmViU0xNYVNZejhOUS1XeFJVR3A2VzQ2MjAweE9EdHJJVzhMV0cxYUM0eF9CV0drVXhwbmQ2bHF2YzE5U2M5V0I5cUhtMXdFM1NjckE1dGhXR21uMzBfeWtaWEtkMkdkZnFZd1NDc3NldFFmVndCUEF3elRtNUJGMUpkLWF0UV9ITHpTOURBVS1KY3ZTN24tMWMzMlEyaGdVUXlLZ2JFRE5wWHhUODVFRGxfQlJTSXVkeTMtclBIbXVSQjJEdGxOSHFYdmxvRmtYUDN5RDdIY1NaRmZhQlpORm1oeXo1alRXbzh6SVUzT25SUlhWN3RXMkJJX1dFS2MyTF8wVjZzVGRqNkU?oc=5","date":"2025-10-23","type":"pipeline","source":"PR Newswire","summary":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight - PR Newswire","headline":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Dia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAJBVV95cUxNZGtWZHFNbTBHS1YyTU1ENWd4Y09VQ3ZPbWQ2NmZyUHlVbl8zdU5JR1hwbl9aN2xQdlNHaWNSdWV4cjlOdEhHMGVSeEtkaWlVOFN5dGRZZHRHLUN4b1dBUmFGNGVIcWhTTi1NTnNnb00yUDlkLXRzTWVtTFZyT1ozbUtGTmxlUnZzZmEwQkZXSEVIXzR1VkxDWlluLVRXR0tDdTZteTQ0V2ZFbGM3TmJjVWM1TEI4MUlHWnRCOEwydmx6YUtreVMybWJoUWxkSkZtb3dYb1VJNjVLSTdFNWotdGY1ZnlxdnNRWkt1Q2VCeGVvbVpfUWptOXlISkhNZ01FQWF3Zks5YWVJQ0FVYkVpV2x1TnVTdVpK?oc=5","date":"2025-06-09","type":"regulatory","source":"PR Newswire","summary":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020-2034) | DelveInsight - PR Newswire","headline":"HER2+ Gastric Cancer (including GEJ) Market to Increase at a Remarkable Growth Rate of 13% During the Study Period (2020","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOODA3S0dwYnpJV3Y1aEVqQS1JWThWTWxNYVI3OHcxY3Z1enJKOE1mQXJZb2xMc0lpamxGb2ZVQ284YVhfcC1YUWQ1WDdRY0o0SkhmYkFLOEoxOFJJa082ZG9TSEN6TklYWnhZRldPNHlLekdndExldTlOWUpYOE1uQnpQaEN6VmVSWlQ5c1JBanNrRC1yTC1N?oc=5","date":"2023-04-19","type":"trial","source":"Yahoo Finance","summary":"Mesothelioma Clinical Trials Pipeline Analysis: 50+ Companies are Working to Improve the Treatment Space | DelveInsight - Yahoo Finance","headline":"Mesothelioma Clinical Trials Pipeline Analysis: 50+ Companies are Working to Improve the Treatment Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQTGExV1FFOTQxRVIyLXc5VkxhZUFaMGJIWXJFUFdsM1NtSVZnaVBEVDNxMzhjM01meHlaVG0zVGhSTEEzLXVMQmNWd1J6SlFrOGoyeTlpdkNyTXp2aWJobWhLc1hEbkpKTkRNb3N4U3dsMWl0ajVrcnJYd0V4Skxrb19QZTk5RnkyTnBxZ3pDMm5nZ2RMd3BubXNMQlhnNWlwVXF5VW5HSTc0TVFIU3NJZ2ZIUFQzN1d0aUhQTGxBMlg5ejhsVEZSNw?oc=5","date":"2015-09-08","type":"pipeline","source":"PR Newswire","summary":"Purdue Pharma L.P. Announces Acquisition of TrkA Program from VM Pharma LLC - PR Newswire","headline":"Purdue Pharma L.P. Announces Acquisition of TrkA Program from VM Pharma LLC","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}